Ziccum CEO Ann Gidner shared insights in an interview at BioStock Investing in Life Science: From Seed to Success, held in Stockholm on September 12th, 2024, discussing the groundbreaking LaminarPace technology that fully unlocks the potential of mRNA.
This innovative technology utilizes mass transfer, not heat, to convert fragile liquid biologics into robust, thermostable, high-yield dry powders, opening the door to entirely new drug delivery options and offering exciting possibilities for therapeutic applications, such as inhalable mRNA—a true game changer for the biopharmaceutical industry.
To learn more, watch the full interview here: Ziccum | INTERVIEW | Investing in Life Science 2024 (youtube.com)